for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Daito Pharmaceutical Co.,Ltd.

4577.T

Latest Trade

3,520.00JPY

Change

-10.00(-0.28%)

Volume

44,400

Today's Range

3,465.00

 - 

3,545.00

52 Week Range

2,730.00

 - 

3,750.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Medical System Network unit says business alliance with Daito Pharmaceutical

Feb 16 (Reuters) - Medical System Network Co Ltd <4350.T>:Says Sapporo-based pharmaceutical unit forms business alliance with Daito Pharmaceutical Co Ltd <<<4577.T>>> on Feb. 16, and mainly cooperate on provision of joint developed drug .

Daito Pharmaceutical to build new building for pharmaceutical production

July 11 (Reuters) - Daito Pharmaceutical Co Ltd <4577.T>:* Says it will build a new building for pharmaceutical production in October and invest 3.5 billion yen .

Daito Pharmaceutical says Yoshihiro Narai to resign as chairman

Daito Pharmaceutical Co Ltd <4577.T>:Says Yoshihiro Narai to resign as chairman on Jan. 5, 2017.

Daito Pharmaceutical to pay mid-term dividend and revises year-end dividend forecast for FY 2015

Daito Pharmaceutical Co Ltd:To pay mid-term dividend of 15 yen per share, above latest dividend forecast of 0 yen per share, for fiscal year ending May 2015.Record date Nov. 30, 2014 and effective date Feb. 2.Revised year-end dividend forecast to 15 yen per share from 30 yen per share, for fiscal year 2015.

Daito Pharmaceutical Co Ltd confirms share number of private placement

Daito Pharmaceutical Co Ltd:To issue 195,000 new shares, at paid-in price of 1,668.86 yen per share (325,427,700 yen in total), through private placement to Daiwa Securities Co., Ltd., with subscription date Aug. 26 and payment date Aug. 27.

Daito Pharmaceutical Co Ltd announces share price

Daito Pharmaceutical Co Ltd:To issue 1,300,000 new shares at paid-in price of 1,668.86 yen per share (2,169,518,000 yen in total), through public offering, with subscription date from July 23 to July 24 and payment date on July 29.To issue 195,000 new shares, at paid-in price of 1,668.86 yen per share (up to 325,427,700 yen in total), through private placement to Daiwa Securities Co., Ltd., with subscription date Aug. 26 and payment date Aug. 27.

Daito Pharmaceutical Co Ltd to issue new shares

Daito Pharmaceutical Co Ltd:Resolved to issue 1,300,000 new shares through public offering, and payment date on anyday between July 29 and July 31.Resolved to issue 195,000 new shares, through private placement Daiwa Securities Co., Ltd. and says subscription date Aug. 26 and payment date Aug. 27.Price to be decided and disclosed later.

Nissan Chemical Industries Ltd files lawsuit against companies including Daito Pharmaceutical Co Ltd, Mochida Pharmaceutical Co Ltd, TOWA PHARMACEUTICAL CO LTD and KAKEN PHARMACEUTICAL CO LTD

Daito Pharmaceutical Co Ltd:Nissan Chemical Industries Ltd has filed complaints on Dec. 25 with Tokyo District Court, against companies including Daito Pharmaceutical Co Ltd, Mochida Pharmaceutical Co Ltd, TOWA PHARMACEUTICAL CO LTD, Tsuruhara pharmaceutical Co., Ltd., and KAKEN PHARMACEUTICAL CO LTD.Nissan Chemical is seeking injunctive relief to cease and desist from infringing upon the patent owned by Nissan Chemical relating to a certain crystal form of LIVALO, which is therapeutic agent for hypercholesterolemia.Nissan Chemical says the defendants obtained the marketing approval of the generic drugs of LIVALO dated Aug. 15, and then have started, or have announced to start the sales.

Daito Pharmaceutical Co Ltd to Issue Year-end Dividend for FY 2013

Daito Pharmaceutical Co Ltd announced that it has decided to issue a year-end dividend of JPY 30 per share, above the latest dividend forecast of JPY 25 per share, disclosed on July 10, 2012, to all the shareholders of record as of May 31, 2013, effective August 30, 2013, for the fiscal year ended May 2013.

Daito Pharmaceutical Co Ltd Appoints New Chairman of the Board

Daito Pharmaceutical Co Ltd announced that it has appointed Yoshihiro Narai as Chairman of the Board and Representative Director, to replace Shinjiro Sasayama, effective April 1, 2013.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up